NASDAQ:PHIO Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free PHIO Stock Alerts $0.77 -0.06 (-7.18%) (As of 01:46 PM ET) Add Compare Share Share Today's Range$0.69▼$0.8350-Day Range$0.64▼$1.0852-Week Range$0.50▼$6.85Volume433,951 shsAverage Volume371,916 shsMarket Capitalization$3.54 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Phio Pharmaceuticals alerts: Email Address Phio Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside419.3% Upside$4.00 Price TargetShort InterestHealthy0.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.23Based on 3 Articles This WeekInsider TradingAcquiring Shares$2,275 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.81 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPhio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePhio Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.47% of the float of Phio Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPhio Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Phio Pharmaceuticals has recently decreased by 87.88%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPhio Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhio Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHIO. Previous Next 1.0 News and Social Media Coverage News SentimentPhio Pharmaceuticals has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Phio Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for PHIO on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Phio Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,275.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.77% of the stock of Phio Pharmaceuticals is held by insiders.Percentage Held by Institutions57.31% of the stock of Phio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Phio Pharmaceuticals is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phio Pharmaceuticals is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPhio Pharmaceuticals has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Bull ReportHealthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.Click here to see why this small company is trusted by the Mayo Clinic About Phio Pharmaceuticals Stock (NASDAQ:PHIO)Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.Read More PHIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHIO Stock News HeadlinesApril 22, 2024 | benzinga.comWhy Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday?April 22, 2024 | finance.yahoo.comIntratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 22, 2024 | globenewswire.comIntratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsApril 16, 2024 | globenewswire.comPhio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)April 11, 2024 | globenewswire.comPhio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)April 3, 2024 | finance.yahoo.comNational Spotlight Features Phio’s Innovative RNAi Technology PlatformApril 3, 2024 | globenewswire.comNational Spotlight Features Phio's Innovative RNAi Technology PlatformApril 23, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.April 2, 2024 | globenewswire.comPhio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business UpdateMarch 21, 2024 | finance.yahoo.comPhio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesMarch 13, 2024 | globenewswire.comPhio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity ResearchMarch 10, 2024 | morningstar.comPhio Pharmaceuticals Corp PHIOMarch 6, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Neurogene (NGNE), Akero Therapeutics (AKRO)March 6, 2024 | finance.yahoo.comPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin DisordersMarch 6, 2024 | globenewswire.comPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin DisordersFebruary 14, 2024 | uk.finance.yahoo.comDry Age Related Macular Degeneration Market Report 2024: Global Trends, Forecasts and Competitive Analysis 2018-2023 and 2024-2030February 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Phio Pharmaceuticals (PHIO)January 31, 2024 | finance.yahoo.comPhio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesDecember 19, 2023 | msn.comPhio Pharmaceuticals files to sell 4.42M shares of common stock for holdersDecember 7, 2023 | msn.comWhy Phio Pharmaceuticals Stock Is NosedivingDecember 7, 2023 | finance.yahoo.comPhio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross ProceedsNovember 10, 2023 | finanznachrichten.dePhio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 10, 2023 | msn.comPhio Pharmaceuticals GAAP EPS of -$1.14 beats by $0.29November 9, 2023 | finance.yahoo.comPhio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 9, 2023 | finance.yahoo.comPhio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin CarcinomasNovember 3, 2023 | finanznachrichten.dePhio Pharmaceuticals Corp.: Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor ControlSee More Headlines Receive PHIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PHIO CUSIPN/A CIK1533040 Webphiopharma.com Phone(508) 767-3861Fax508-767-3862Employees9Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+447.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($5.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-134.66% Return on Assets-105.86% Debt Debt-to-Equity RatioN/A Current Ratio5.70 Quick Ratio5.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.06 per share Price / Book0.35Miscellaneous Outstanding Shares4,590,000Free Float4,557,000Market Cap$3.35 million OptionableNot Optionable Beta1.44 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Robert J. Bitterman (Age 73)President, CEO & Chairman Comp: $141.46kMs. Caitlin Kontulis (Age 38)VP of Finance & Administration and Secretary Ms. Linda M. MahoneySenior Vice President of DevelopmentKey Competitors60 Degrees PharmaceuticalsNASDAQ:SXTPAtrecaNASDAQ:BCELAraviveNASDAQ:ARAVTransCode TherapeuticsNASDAQ:RNAZNovaBay PharmaceuticalsNYSE:NBYView All CompetitorsInsidersRobert J BittermanBought 2,500 shares on 2/26/2024Total: $2,275.00 ($0.91/share)Robert J BittermanBought 1,000 shares on 6/30/2023Total: $2,880.00 ($2.88/share)Robert L FerraraBought 2,000 shares on 6/14/2023Total: $6,200.00 ($3.10/share)View All Insider Transactions PHIO Stock Analysis - Frequently Asked Questions Should I buy or sell Phio Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PHIO shares. View PHIO analyst ratings or view top-rated stocks. What is Phio Pharmaceuticals' stock price target for 2024? 1 Wall Street analysts have issued 1-year target prices for Phio Pharmaceuticals' stock. Their PHIO share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 419.3% from the stock's current price. View analysts price targets for PHIO or view top-rated stocks among Wall Street analysts. How have PHIO shares performed in 2024? Phio Pharmaceuticals' stock was trading at $0.76 on January 1st, 2024. Since then, PHIO shares have increased by 1.4% and is now trading at $0.7703. View the best growth stocks for 2024 here. Are investors shorting Phio Pharmaceuticals? Phio Pharmaceuticals saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 21,400 shares, a drop of 87.9% from the March 15th total of 176,600 shares. Based on an average daily trading volume, of 314,300 shares, the short-interest ratio is presently 0.1 days. Approximately 0.5% of the company's stock are sold short. View Phio Pharmaceuticals' Short Interest. When is Phio Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PHIO earnings forecast. How were Phio Pharmaceuticals' earnings last quarter? Phio Pharmaceuticals Corp. (NASDAQ:PHIO) released its earnings results on Wednesday, November, 10th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.03. What other stocks do shareholders of Phio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Akero Therapeutics (AKRO), Boxlight (BOXL), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Jaguar Health (JAGX) and Milestone Pharmaceuticals (MIST). How do I buy shares of Phio Pharmaceuticals? Shares of PHIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PHIO) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.